当前位置: 首页 >> 检索结果
82. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.
作者: Hairong Xu.;Xiaohui Niu.;Vinod Ravi.;Javier Martin-Broto.;Albiruni Abdul Razak.;Ramy Saleh.;Yong Zhou.;Jingnan Shen.;Tang Liu.;Kamlesh Kumar Sankhala.;César Serrano.;Silvia Stacchiotti.;Jing Wang.;Giacomo G Baldi.;Yi Feng.;Yingqi Hua.;Tao Li.;Piotr Rutkowski.;Xiaojing Zhang.;Gabriel Tinoco.;Qingping Zou.;Boyao Shan.;Xiangyu Zhu.;Hans Gelderblom.
来源: Lancet. 2026年407卷10533期1072-1083页
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm that affects otherwise healthy adults. There are few systemic treatment options, highlighting an unmet need. We report the results of part 1 of the MANEUVER trial, which aimed to evaluate the efficacy and safety of pimicotinib, a highly selective, potent, colony-stimulating factor-1 receptor inhibitor, in patients with TGCT.
85. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Michel Azizi.;Jenifer M Brown.;Jamie P Dwyer.;John M Flack.;Erica S W Jones.;Raisa Kurlyandskaya.;Hongjian Li.;Filip Birve.;Aina S Lihn.;Shira Perl.;Markus P Schlaich.;Hirotaka Shibata.;Ji-Guang Wang.;Bryan Williams.; .
来源: Lancet. 2026年407卷10532期988-999页
Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension.
86. 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.
作者: Sofia Rivera.;Robabeh Ghodssighassemabadi.;Guillaume Auzac.;Thomas Brion.;Youlia Kirova.;Séverine Racadot.;Mohamed Benchalal.;Jean-Baptiste Clavier.;Claire Charra Brunaud.;Anais Groulier.;Delphine Argo-Leignel.;Karine Peignaux.;Ahmed Benyoucef.;David Pasquier.;Philippe Guilbert.;Aurore Goineau.;Agnes Tallet.;Marie Bergeaud.;Assia Lamrani-Ghaouti.;Stefan Michiels.; .
来源: Lancet. 2026年407卷10532期976-987页
Hypofractionated radiotherapy is standard for whole-breast radiotherapy, but 50 Gy in 25 fractions (5-week radiotherapy) is still standard in many countries when nodal radiotherapy is needed for morbidity concerns. The UNICANCER HypoG-01 trial aimed to assess morbidity and efficacy of hypofractionated locoregional radiotherapy delivering 40 Gy in 15 fractions (3-week radiotherapy) versus 5-week radiotherapy.
98. When the rules are rewritten, strengthen the coalition for gender justice.
作者: Sarah Hawkes.;Kent Buse.;Jocalyn P Clark.;Raewyn Connell.;Beniamino Cislaghi.;Gary L Darmstadt.;Carmen Simone Grilo Diniz.;Indrani Gupta.;Amy Chiaying Hsieh.;Jeni Klugman.;Erica Nelson.;Ravi Verma.;Elhadj As Sy.
来源: Lancet. 2026年407卷10532期929-931页 99. Why investing in women's health is a societal imperative.
作者: Isa Bijloo.;Noa S de Smit.;Felicia Yarde.;Wouter J K Hehenkamp.;Carmen van Vilsteren.;Derrick Z W Khor.;Chiara Benedetto.;Mathew Leonardi.;Lesley Regan.;Tina Tellum.;Judith A F Huirne.
来源: Lancet. 2026年407卷10532期926-929页 |